112 related articles for article (PubMed ID: 12629945)
1. Outpatient administration of radiolabeled monoclonal antibodies.
Tuinstra N
Clin J Oncol Nurs; 2003; 7(1):106-8. PubMed ID: 12629945
[No Abstract] [Full Text] [Related]
2. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
3. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
[TBL] [Abstract][Full Text] [Related]
4. The radiation biology of radioimmunotherapy.
Dixon KL
Nucl Med Commun; 2003 Sep; 24(9):951-7. PubMed ID: 12960593
[TBL] [Abstract][Full Text] [Related]
5. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens.
Reilly RM
J Nucl Med; 2006 Feb; 47(2):196-9. PubMed ID: 16455623
[No Abstract] [Full Text] [Related]
7. Radioimmunotherapy. Progress, potential and problems.
Mather SJ; Britton KE
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):248-50. PubMed ID: 15640787
[No Abstract] [Full Text] [Related]
8. Principles of radioimmunotherapy for hematologists and oncologists.
Press OW; Rasey J
Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
[TBL] [Abstract][Full Text] [Related]
11. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
Juweid M; Sharkey RM; Swayne LC; Griffiths GL; Dunn R; Goldenberg DM
J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735
[TBL] [Abstract][Full Text] [Related]
13. Antibody-guided radiation therapy of cancer.
Koppe MJ; Postema EJ; Aarts F; Oyen WJ; Bleichrodt RP; Boerman OC
Cancer Metastasis Rev; 2005 Dec; 24(4):539-67. PubMed ID: 16408161
[TBL] [Abstract][Full Text] [Related]
14. Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides.
Rao DV; Howell RW
J Nucl Med; 1993 Oct; 34(10):1801-10. PubMed ID: 8410301
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy.
Colnot DR; Wilhelm AJ; Cloos J; Roos JC; de Bree R; Quak JJ; Snow GB; van Dongen GA
J Nucl Med; 2001 Sep; 42(9):1364-7. PubMed ID: 11535726
[TBL] [Abstract][Full Text] [Related]
16. Systemic targeted radionuclide therapy: potential new areas.
Wong JY
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S74-82. PubMed ID: 16979445
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of malignancies.
Reilly RM
Clin Pharm; 1991 May; 10(5):359-75. PubMed ID: 2049898
[TBL] [Abstract][Full Text] [Related]
18. Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma.
Zeng ZC; Tang ZY; Yang BH; Liu KD; Wu ZQ; Fan J; Qin LX; Sun HC; Zhou J; Jiang GL
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1657-68. PubMed ID: 12458401
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeled antibodies: results and potential in cancer therapy.
Order SE; Sleeper AM; Stillwagon GB; Klein JL; Leichner PK
Cancer Res; 1990 Feb; 50(3 Suppl):1011s-1013s. PubMed ID: 2404579
[TBL] [Abstract][Full Text] [Related]
20. Pretargeted radioimmunotherapy of cancer: progress step by step.
Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]